CJC-1295 (no dac) 5MG

CJC-1295 is a long-acting synthetic analogue of Growth Hormone-Releasing Hormone (GHRH) that stimulates the pituitary gland. Its modification with a Drug Affinity Complex (DAC) dramatically extends its half-life, making it a subject of intense research for its ability to provide sustained increases in Growth Hormone and IGF-1 levelsCJC-1295 (No DAC) is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH) designed to stimulate the pituitary gland to increase natural Growth Hormone secretion. Unlike the DAC-modified version, CJC-1295 without DAC has a much shorter half-life and acts more like the body’s natural pulsatile GHRH. It is commonly examined in research for its ability to promote brief, physiologic increases in Growth Hormone and IGF-1 levels without the prolonged elevation associated with the DAC-attached form.

$50.00

The information provided on this page is intended solely as a general summary. It does not encompass all potential research applications, handling procedures, safety precautions, interactions, or observed effects. These products are supplied strictly for laboratory and research purposes only. They are not intended for human consumption, medical use, veterinary use, or diagnostic purposes. This information must not be considered a substitute for professional expertise, judgment, or regulatory guidance.

Money Back Guarantee

Guaranteed Quality

Fast Shipping

10+ Years Experience

Frequently Bought Together

Original price was: $50.00.Current price is: $45.00.
Original price was: $50.00.Current price is: $45.00.
Original price was: $125.00.Current price is: $79.20.
Original price was: $120.00.Current price is: $81.00.
Original price was: $345.00.Current price is: $250.20.
For 4 items

SEQUENCE/FORMULA

Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg Molecular Formula: C152H252N44O42

MOLECULAR WEIGHT

Approx. 3367.9 g/mol

PUBCHEM CID

56841944
  • Investigating its effects on producing a short, pulsatile release of growth hormone (GH), mimicking the body's natural secretion patterns.
  • Studying its use in protocols that may require multiple administrations to maintain elevated GH and IGF-1 levels.
  • Analyzing its potential to support increases in lean body mass and reductions in adipose tissue (fat).
  • Researching its role in promoting tissue repair and recovery due to its effects on GH secretion.
  • Exploring its connection to improved slow-wave sleep.
  • Functions as a potent synthetic analogue of Growth Hormone-Releasing Hormone (GHRH).
  • It contains four substituted amino acids in its chain which protect it from rapid enzymatic degradation, making it more stable than native GHRH.
  • It binds to GHRH receptors in the anterior pituitary gland, stimulating a strong but short-lived pulse of growth hormone.
  • Unlike CJC-1295 with DAC, it does not bind to serum albumin and has a much shorter half-life of approximately 30 minutes.
  • Walker, R. F. (2006). Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clinical Interventions in Aging, 1(4), 307–308.
  • Alba, M., et al. (2006). The GHRH receptor: its involvement in the regulation of growth and metabolism. Reviews in Endocrine and Metabolic Disorders, 7(3), 133-140.
  • Prakash, A., & Goa, K. L. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs, 12(2), 139-157.